The class action charges Telix with violating the Securities Exchange Act of 1934 by allegedly failing to disclose that: 1. Overstated Therapeutic Progress: Management materially overstated the ...
Overstated Therapeutic Progress: Management materially overstated the developmental progress and commercial prospects of its prostate cancer therapeutic candidates, specifically TLX591 and TLX592.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback